January 24 (SeeNews) - Belgian specialty biopharma company Hyloris has signed an exclusive licensing and distribution agreement with Slovenian pharmaceutical products wholesaler Salus [LJE:SALR] for its non-opioid pain treatment Maxigesic, Hyloris said on Tuesday.
The agreement with Salus Pharmaceuticals encompasses the markets of Lithuania, Estonia, Latvia, Croatia, Slovenia, Serbia, North Macedonia, Montenegro, and Bosnia, Hyloris said in a statement.
Maxigesic is already registered in Lithuania, Estonia, Latvia, Croatia and Slovenia, where the first commercial launches are expected later this year, while registration applications will be filed in Serbia, North Macedonia, Montenegro and Bosnia, the company said.
"This novel non-opioid pain treatment can soon offer relief to patients in even more countries across Europe, and underlines the attractiveness of our business model of reformulating and repurposing existing medicinal products, including its ability to provide significant benefits to patients and health care providers," Hyloris CEO Stijn Van Rompay said in the statement.
Maxigesic represents a pain treatment for use post-operatively in hospitals or when patients cannot take medicine orally.